Literature DB >> 15293105

Antiphospholipid and antisynthetase syndrome in a patient with polymyositis-rheumatoid arthritis overlap.

Andrea Ponyi1, Tamás Constantin, Katalin Dankó.   

Abstract

Idiopathic inflammatory myopathies, mainly polymyositis (PM) may occur in the course of several autoimmune diseases. The overlapping forms of myositis, when the patient also meets the criteria for rheumatoid arthritis (RA), affect 3%-5% of myositis patients [1]. To the best of our knowledge this is the first report on the overlapping form of RA, antiphospholipid syndrome (APS) and the serological subgroup of PM, the antisynthetase syndrome (ASS).

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15293105     DOI： 10.1007/s10067-004-0903-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  9 in total

1.  Juvenile dermatomyositis with major thrombosis-an unusual course.

Authors:  C Huemer; M Duesse; W Seerainer; G Lubec
Journal:  Clin Exp Rheumatol       Date:  1995 Nov-Dec       Impact factor: 4.473

Review 2.  Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance.

Authors:  P E Love; S A Santoro
Journal:  Ann Intern Med       Date:  1990-05-01       Impact factor: 25.391

3.  The anticardiolipin syndrome.

Authors:  G R Hughes; N N Harris; A E Gharavi
Journal:  J Rheumatol       Date:  1986-06       Impact factor: 4.666

4.  Myositis-specific autoantibodies. Touchstones for understanding the inflammatory myopathies.

Authors:  F W Miller
Journal:  JAMA       Date:  1993-10-20       Impact factor: 56.272

5.  Dermatomyositis and polymyositis associated with the antiphospholipid syndrome-a novel overlap syndrome.

Authors:  Y Sherer; A Livneh; Y Levy; Y Shoenfeld; P Langevitz
Journal:  Lupus       Date:  2000       Impact factor: 2.911

6.  The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases.

Authors:  P A Merkel; Y Chang; S S Pierangeli; K Convery; E N Harris; R P Polisson
Journal:  Am J Med       Date:  1996-12       Impact factor: 4.965

7.  A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.

Authors:  L A Love; R L Leff; D D Fraser; I N Targoff; M Dalakas; P H Plotz; F W Miller
Journal:  Medicine (Baltimore)       Date:  1991-11       Impact factor: 1.889

8.  Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity.

Authors:  M B Mathews; R M Bernstein
Journal:  Nature       Date:  1983 Jul 14-20       Impact factor: 49.962

9.  Dermatopolymyositis and other connective tissue diseases: a review of 105 cases.

Authors:  K E Tymms; J Webb
Journal:  J Rheumatol       Date:  1985-12       Impact factor: 4.666
  9 in total
  4 in total

1.  Antisynthetase syndrome with rare EJ-1 antibodies with antiphospholipid syndrome.

Authors:  Louis Chhor; Steven Tu; Paul Fogarty; Christopher Fong
Journal:  Respirol Case Rep       Date:  2022-06-13

Review 2.  Development of antisynthetase syndrome in a patient with rheumatoid arthritis.

Authors:  Cheol-Kyu Park; Tae-Jong Kim; Young-Nan Cho; Il-Soo Kim; Ho-Jun Lee; Kyung-Eun Lee; Seong-Chang Park; Jong-Sun Kim; Dong-Jin Park; Sung-Ji Lee; Seong-Rye Seo; Jeong-Chul Kim; Sang-Gook Song; Shin-Seok Lee; Yong-Wook Park
Journal:  Rheumatol Int       Date:  2009-10-22       Impact factor: 2.631

Review 3.  Beneficial effect of treatment with cyclosporin A in a case of refractory antisynthetase syndrome.

Authors:  Magdalena Jankowska; Barbara Butto; Alicja Debska-Slizień; Bolesław Rutkowski
Journal:  Rheumatol Int       Date:  2007-01-13       Impact factor: 3.580

4.  Anti-synthetase syndrome in a patient with recurrent episodes of pulmonary embolism: a case report.

Authors:  Moemen Eltelbany; Yuting Huang; Preetinder Sandhu; Abdul Akbaryeh; Nzube Iloh; Dena H Tran; Jamal Mikdashi; Iram Bakhtawar
Journal:  J Community Hosp Intern Med Perspect       Date:  2020-06-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.